Review of outcome measurement instruments in Alzheimer's disease drug trials: Psychometric properties of global scales

Journal of Geriatric Psychiatry and Neurology

Volumn 13, Issue 4, 2000, Pages 197-205

  Oremus, Mark ^a,b   Perrault, Anne ^a,c   Demers, Louise ^a,b,c   Wolfson, Christina ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CENTRE DE RECHERCHE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; RELIABILITY; REVIEW; SCORING SYSTEM; STATISTICAL ANALYSIS; VALIDATION PROCESS;

EID: 0034520313     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/089198870001300404     Document Type: Review

References (58)

1. Mild senile dementia of the Alzheimer type: 2. Longitudinal assessment
2. The Global Deterioration Scale for assessment of primary degenerative dementia
3. Primary outcome measures in dementia drug trials: Modified Clinical Interview-Based Impression of Change (CIBIC-M)
4. Factors determining interrater agreement with rating global change in dementia: The CIBIC-plus
5. The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease
6. Clinical global impressions in Alzheimer's clinical trials
7. Reliability and clinical concepts underlying global judgments in dementia: Implications for clinical research
8. A psychometric evaluation of dementia rating scales
9. Determinants of global clinical change assessment in patients with early Alzheimer's disease
10. Donepezil improves cognition and global function in Alzheimer disease, a 15-week, double-blind, placebo-controlled study
11. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
12. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
13. The effects of donepezil in Alzheimer's disease - Results from a multinational trial
14. Development standards for health measures
15. A new clinical scale for the staging of dementia
16. The Clinical Dementia Rating (CDR): Current version and scoring rules
17. The Clinical Dementia Rating Scale: Community-based validation of 'profound' and 'terminal' stages
18. Clinical Dementia Rating (CDR)
19. Reliability of the Washington University Clinical Dementia Rating
20. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines
21. Clinical Dementia Rating training and reliability in multicenter studies: The Alzheimer's Disease Cooperative Study experience
22. Reliability of clinical nurse specialists in the staging of dementia
23. Comparison of seven psychometric instruments used for evaluation of treatment effect in Alzheimer's dementia
24. Staging the severity of dementia: Comparison of clinical (CDR, DSM-III-R), functional (ADL, IADL) and cognitive (MMSE) scales
25. Estimating the validity of the Clinical Dementia Rating Scale: The CERAD experience
26. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's Disease
27. Symptomatology: Functional capacity and behaviour
28. Defining meaningful change in Alzheimer's disease trials: The donepezil experience
29. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention
30. Management of dementing disorders: Conclusions from the Canadian Consensus Conference on Dementia
31. Global Deterioration Scale (GDS)
32. Longitudinal study of dementia patients and aged controls
33. Reliability of psychiatric scales in patients with dementia of the Alzheimer type
34. Psychiatric assessment in medical long-term care facilities: Reliability of commonly used rating scales
35. Staging methods for the assessment of dementia: Perspectives
36. The MDS Cognition Scale: A valid instrument for identifying and staging nursing home residents with dementia using the Minimum Data Set
37. Goal attainment scaling as a measure of clinically important change in nursing-home patients
38. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease
39. Sample size in factor analysis
40. Sample size requirements for precise estimates of reliability, generalizability, and validity coefficients
41. An example of a clinical trial in patients with Alzheimer's disease: Some methodological issues
42. Meta-analyses of validity studies published between 1964 and 1982 and the investigation of study characteristics
43. Sample size in validity studies of personnel selection
44. Sample size requirements for increasing the precision of reliability estimates: Problems and proposed solutions
45. Sample size requirements for reliability studies
46. Sample size and optimal designs for reliability studies
47. Weighted kappa: Nominal scale agreement with provision for scaled disagreement or partial credit
48. A coefficient of agreement for nominal scales
49. Effect sizes for interpreting changes in health status
50. Issues in the use of change scores in randomized trials
51. How should we measure "change" - Or should we?
52. Measuring change over time: Assessing the usefulness of evaluative instruments
53. Can the sickness impact profile measure change? An example of scale assessment
54. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease